LYON, France, May 25, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced two abstracts supporting the Ablatherm® High Intensity Focused Ultrasound's (HIFU) efficacy for the treatment of localized prostate cancer will be featured at the 4th International Symposium on Focal Therapy & Imaging in Prostate & Kidney Cancer, held on May 25 – 27, 2011 in Amsterdam, Netherlands. EDAP will feature its Ablatherm-HIFU technology at its booth.
